Abstract
Renal cell carcinoma is a devastating disease that oftentimes results in a poor prognosis because there are few effective chemotherapeutic options. The renal carcinoma cell line 769-P is an ideal in vitro model for investigating novel drug treatments for renal cell carcinoma. Two drugs that may potentially reduce renal cell carcinoma proliferation are Actinomycin D and phorbol 12-myristate 13 acetate (PMA). Both of these drugs have been shown to inhibit cell proliferation in other in vitro models of cancer. This study examined the effects of Actinomycin D and PMA treatment on the proliferation of 769-P cells. Cell viability studies indicate that ...
